Company OverviewStella Diagnostics
Stella Diagnostics, Inc. (OTC:SLDX) is a molecular diagnostics-based organization focused on improving patient management strategies for over 60 million people living with severe esophageal disease. Stella Diagnostic's mass spec proteomic assays will offer physicians insight into the molecular properties of their patients’ tissue to determine if the disease is stable, progressing or turning cancerous. Stella Diagnostics is developing first-line diagnostic tools that provides superior molecular information for providers as compared to the current standard screening protocols.
Speaker BioCEO
Stella Diagnostics
Joe Abdo has over a decade of experience in molecular oncology research, R&D and business development in both private and public biotechnology organizations. Dr. Abdo has won several awards for his research and has published over a dozen articles and a text book in the fields of molecular oncology, proteomics, genomics, immunotherapy and gastrointestinal diseases, placing advancements in patient care at the forefront of his work.
He earned a PhD in Clinical and Translational Science from Creighton University School of Medicine where he investigated biochemical mechanisms of Barrett’s-related esophageal adenocarcinoma. He also received a Master’s degree in Biotechnology from Georgetown University School of Medicine where he researched genomic and proteomic expression abnormalities in patients with gastro-intestinal diseases. Most recently, he was the Senior Director of Clinical and Translational Science at PolarityTE, MD Inc.
